Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.61 |
| ▸ | CCKAR | P32238 | 8/20 | 0.41 |
| ▸ | CCKBR | P32239 | 8/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13880567 | 0.93 | GLP1R (0.62) | GLP1RCCKARCCKBRNOD1 | |
| SCHEMBL25465163 | 0.93 | GLP1R (0.62) | GLP1RCCKARCCKBRNOD1 | |
| SCHEMBL13577576 | 0.91 | GLP1R (0.76) | GLP1RCCKARCCKBRNOD1 | |
| SCHEMBL13577532 | 0.90 | GLP1R (0.69) | GLP1RCCKARCCKBRNOD1 | |
| SCHEMBL14819894 | 0.89 | GLP1R (0.68) | GLP1RCCKARCCKBR | |
| SCHEMBL12743611 | 0.88 | GLP1R (0.46) | GLP1RCCKARCCKBRC3AR1 | |
| SCHEMBL12807268 | 0.88 | GLP1R (0.46) | GLP1RCCKARCCKBRC3AR1 | |
| SCHEMBL8115663 | 0.85 | GLP1R (0.51) | GLP1RCCKARCCKBR | |
| SCHEMBL14685802 | 0.85 | GLP1R (0.65) | GLP1RCCKARCCKBRC3AR1NOD1 | |
| SCHEMBL19155407 | 0.85 | GLP1R (0.62) | GLP1RCCKARCCKBRC3AR1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209056-A1 | GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209056-A1 | GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE | GIPR, GLP1R, GCGR | GLP1R 2/4885CCKAR 10/4885CCKBR 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.